250 related articles for article (PubMed ID: 35679476)
21. Axicabtagene Ciloleucel: Clinical Data for the Use of CAR T-cell Therapy in Relapsed and Refractory Large B-cell Lymphoma.
Halford Z; Anderson MK; Bennett LL
Ann Pharmacother; 2021 Mar; 55(3):390-405. PubMed ID: 32698673
[TBL] [Abstract][Full Text] [Related]
22. Safety and Efficacy of Axicabtagene Ciloleucel versus Standard of Care in Patients 65 Years of Age or Older with Relapsed/Refractory Large B-Cell Lymphoma.
Westin JR; Locke FL; Dickinson M; Ghobadi A; Elsawy M; van Meerten T; Miklos DB; Ulrickson ML; Perales MA; Farooq U; Wannesson L; Leslie L; Kersten MJ; Jacobson CA; Pagel JM; Wulf G; Johnston P; Rapoport AP; Du L; Vardhanabhuti S; Filosto S; Shah J; Snider JT; Cheng P; To C; Oluwole OO; Sureda A
Clin Cancer Res; 2023 May; 29(10):1894-1905. PubMed ID: 36999993
[TBL] [Abstract][Full Text] [Related]
23. A real-world comparison of tisagenlecleucel and axicabtagene ciloleucel CAR T cells in relapsed or refractory diffuse large B cell lymphoma.
Bachy E; Le Gouill S; Di Blasi R; Sesques P; Manson G; Cartron G; Beauvais D; Roulin L; Gros FX; Rubio MT; Bories P; Bay JO; Llorente CC; Choquet S; Casasnovas RO; Mohty M; Guidez S; Joris M; Loschi M; Carras S; Abraham J; Chauchet A; Drieu La Rochelle L; Deau-Fischer B; Hermine O; Gastinne T; Tudesq JJ; Gat E; Broussais F; Thieblemont C; Houot R; Morschhauser F
Nat Med; 2022 Oct; 28(10):2145-2154. PubMed ID: 36138152
[TBL] [Abstract][Full Text] [Related]
24. Quality-Adjusted Time without Symptoms or Toxicity: Analysis of Axicabtagene Ciloleucel versus Standard of Care in Patients with Relapsed/Refractory Large B Cell Lymphoma.
Kersten MJ; Qiao Y; Shah R; Solem C; Snider JT; To C; Cheng P; Spooner C; Perales MA
Transplant Cell Ther; 2023 May; 29(5):335.e1-335.e8. PubMed ID: 36646322
[TBL] [Abstract][Full Text] [Related]
25. Axicabtagene ciloleucel vs standard of care in second-line large B-cell lymphoma: outcomes by metabolic tumor volume.
Locke FL; Oluwole OO; Kuruvilla J; Thieblemont C; Morschhauser F; Salles G; Rowe SP; Vardhanabhuti S; Winters J; Filosto S; To C; Cheng P; Schupp M; Korn R; Kersten MJ
Blood; 2024 Jun; 143(24):2464-2473. PubMed ID: 38557775
[TBL] [Abstract][Full Text] [Related]
26. A phase 2 study of axicabtagene ciloleucel in relapsed or refractory large B-cell lymphoma in Japan: 1-year follow-up and biomarker analysis.
Kato K; Fujii N; Makita S; Goto H; Kanda J; Shimada K; Akashi K; Izutsu K; Teshima T; Fukuda N; Sumitani T; Nakamura S; Sumi H; Shimizu S; Kakurai Y; Yoshikawa K; Tobinai K; Usui N; Hatake K
Int J Hematol; 2023 Mar; 117(3):409-420. PubMed ID: 36399286
[TBL] [Abstract][Full Text] [Related]
27. Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma.
Locke FL; Miklos DB; Jacobson CA; Perales MA; Kersten MJ; Oluwole OO; Ghobadi A; Rapoport AP; McGuirk J; Pagel JM; Muñoz J; Farooq U; van Meerten T; Reagan PM; Sureda A; Flinn IW; Vandenberghe P; Song KW; Dickinson M; Minnema MC; Riedell PA; Leslie LA; Chaganti S; Yang Y; Filosto S; Shah J; Schupp M; To C; Cheng P; Gordon LI; Westin JR;
N Engl J Med; 2022 Feb; 386(7):640-654. PubMed ID: 34891224
[TBL] [Abstract][Full Text] [Related]
28. Matching-adjusted indirect treatment comparison of liso-cel versus axi-cel in relapsed or refractory large B cell lymphoma.
Maloney DG; Kuruvilla J; Liu FF; Kostic A; Kim Y; Bonner A; Zhang Y; Fox CP; Cartron G
J Hematol Oncol; 2021 Sep; 14(1):140. PubMed ID: 34493319
[TBL] [Abstract][Full Text] [Related]
29. A Review of Two Regulatory Approved Anti-CD19 CAR T-Cell Therapies in Diffuse Large B-Cell Lymphoma: Why Are Indirect Treatment Comparisons Not Feasible?
Zhang J; Li J; Ma Q; Yang H; Signorovitch J; Wu E
Adv Ther; 2020 Jul; 37(7):3040-3058. PubMed ID: 32524498
[TBL] [Abstract][Full Text] [Related]
30. Cost-effectiveness analysis of axicabtagene ciloleucel vs. salvage chemotherapy for relapsed or refractory adult diffuse large B-cell lymphoma in China.
Li N; Zheng B; Cai H; Yang T; Hong Y; Liu M; Hu J
Support Care Cancer; 2022 Jul; 30(7):6113-6121. PubMed ID: 35419735
[TBL] [Abstract][Full Text] [Related]
31. The Cost-Effectiveness of Axicabtagene Ciloleucel as Second-Line Therapy in Patients with Large B-Cell Lymphoma in the United States: An Economic Evaluation of the ZUMA-7 Trial.
Perales MA; Kuruvilla J; Snider JT; Vadgama S; Blissett R; El-Moustaid F; Smith NJ; Patel AR; Johnston PB
Transplant Cell Ther; 2022 Nov; 28(11):750.e1-750.e6. PubMed ID: 35970302
[TBL] [Abstract][Full Text] [Related]
32. Cost-effectiveness of axicabtagene ciloleucel versus lisocabtagene maraleucel for adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy in the US.
Oluwole OO; Liu R; Diakite I; Feng C; Patel A; Nourhussein I; Snider JT; Locke FL
J Med Econ; 2022; 25(1):541-551. PubMed ID: 35443867
[TBL] [Abstract][Full Text] [Related]
33. GLA/DRST real-world outcome analysis of CAR T-cell therapies for large B-cell lymphoma in Germany.
Bethge WA; Martus P; Schmitt M; Holtick U; Subklewe M; von Tresckow B; Ayuk F; Wagner-Drouet EM; Wulf GG; Marks R; Penack O; Schnetzke U; Koenecke C; von Bonin M; Stelljes M; Glass B; Baldus CD; Vucinic V; Mougiakakos D; Topp M; Fante MA; Schroers R; Bayir L; Borchmann P; Buecklein V; Hasenkamp J; Hanoun C; Thomas S; Beelen DW; Lengerke C; Kroeger N; Dreger P
Blood; 2022 Jul; 140(4):349-358. PubMed ID: 35316325
[TBL] [Abstract][Full Text] [Related]
34. Benefit of axicabtagene ciloleucel versus chemoimmunotherapy in older patients and/or patients with poor ECOG performance status with relapsed or refractory large B-cell lymphoma after 2 or more lines of prior therapy.
Lunning MA; Wang HL; Hu ZH; Locke FL; Siddiqi T; Jacobson CA; Ahmed S; Miklos DB; Lin Y; Hill BT; Ghobadi A; Neelapu SS; Westin J; Dieyi C; Field P; Miao H; Shahani SA; Patel A; Spooner C; Fu C; Muramoto D; Xu H; Pasquini MC
Am J Hematol; 2024 May; 99(5):880-889. PubMed ID: 38504387
[TBL] [Abstract][Full Text] [Related]
35. The Cost Effectiveness of Axicabtagene Ciloleucel Versus Best Supportive Care in the Treatment of Adult Patients with Relapsed or Refractory Large B-Cell Lymphoma (LBCL) After Two or More Lines of Systemic Therapy in Canada.
Hillis C; Vicente C; Ball G
Pharmacoeconomics; 2022 Sep; 40(9):917-928. PubMed ID: 35844002
[TBL] [Abstract][Full Text] [Related]
36. Matching-adjusted indirect comparison of axi-cel and liso-cel in relapsed or refractory large B-cell lymphoma.
Oluwole OO; Chen JMH; Chan K; Patel AR; Jansen JP; Keeping S; Zheng Y; Snider JT; Locke FL
Leuk Lymphoma; 2022 Dec; 63(13):3052-3062. PubMed ID: 36048026
[TBL] [Abstract][Full Text] [Related]
37. Network meta-analysis of CAR T-Cell therapy for the treatment of 3L+ R/R LBCL after using published comparative studies.
Oluwole OO; Neelapu SS; Ray MD; Limbrick-Oldfield EH; Wade SW; Kanters S; Patel AR; Locke FL
Expert Rev Anticancer Ther; 2024 Jun; 24(6):457-465. PubMed ID: 38646700
[TBL] [Abstract][Full Text] [Related]
38. Patterns of Use, Outcomes, and Resource Utilization among Recipients of Commercial Axicabtagene Ciloleucel and Tisagenlecleucel for Relapsed/Refractory Aggressive B Cell Lymphomas.
Riedell PA; Hwang WT; Nastoupil LJ; Pennisi M; McGuirk JP; Maziarz RT; Bachanova V; Oluwole OO; Brower J; Flores OA; Ahmed N; Schachter L; Bharucha K; Dholaria BR; Schuster SJ; Perales MA; Bishop MR; Porter DL
Transplant Cell Ther; 2022 Oct; 28(10):669-676. PubMed ID: 35850429
[TBL] [Abstract][Full Text] [Related]
39. Earlier corticosteroid use for adverse event management in patients receiving axicabtagene ciloleucel for large B-cell lymphoma.
Topp MS; van Meerten T; Houot R; Minnema MC; Bouabdallah K; Lugtenburg PJ; Thieblemont C; Wermke M; Song KW; Avivi I; Kuruvilla J; Dührsen U; Zheng Y; Vardhanabhuti S; Dong J; Bot A; Rossi JM; Plaks V; Sherman M; Kim JJ; Kerber A; Kersten MJ
Br J Haematol; 2021 Nov; 195(3):388-398. PubMed ID: 34590303
[TBL] [Abstract][Full Text] [Related]
40. FDA Approval Summary: Axicabtagene Ciloleucel for Relapsed or Refractory Follicular Lymphoma.
Bouchkouj N; Zimmerman M; Kasamon YL; Wang C; Dai T; Xu Z; Wang X; Theoret M; Purohit-Sheth T; George B
Oncologist; 2022 Jul; 27(7):587-594. PubMed ID: 35403693
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]